BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spaans VM, Trietsch MD, Crobach S, Stelloo E, Kremer D, Osse EM, Haar NT, van Eijk R, Muller S, van Wezel T, Trimbos JB, Bosse T, Smit VT, Fleuren GJ. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One 2014;9:e93451. [PMID: 24671188 DOI: 10.1371/journal.pone.0093451] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Skorda A, Bay ML, Hautaniemi S, Lahtinen A, Kallunki T. Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises. Cancers (Basel) 2022;14. [PMID: 36551745 DOI: 10.3390/cancers14246257] [Reference Citation Analysis]
2 Holbert CE, Cullen MT, Casero RA Jr, Stewart TM. Polyamines in cancer: integrating organismal metabolism and antitumour immunity. Nat Rev Cancer 2022. [PMID: 35477776 DOI: 10.1038/s41568-022-00473-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
3 Wu H, Chen Z, Wu Y, Zhang H, Liu Q. Integrating Protein-Protein Interaction Networks and Somatic Mutation Data to Detect Driver Modules in Pan-Cancer. Interdiscip Sci 2021. [PMID: 34491536 DOI: 10.1007/s12539-021-00475-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Mustachio LM, Chelariu-Raicu A, Szekvolgyi L, Roszik J. Targeting KRAS in Cancer: Promising Therapeutic Strategies. Cancers (Basel) 2021;13:1204. [PMID: 33801965 DOI: 10.3390/cancers13061204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
5 Richter C, Mayhew D, Rennhack JP, So J, Stover EH, Hwang JH, Szczesna-Cordary D. Genomic Amplification and Functional Dependency of the Gamma Actin Gene ACTG1 in Uterine Cancer. Int J Mol Sci 2020;21:E8690. [PMID: 33217970 DOI: 10.3390/ijms21228690] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zhu DL, Tuo XM, Rong Y, Zhang K, Guo Y. Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers. J Cancer 2020;11:7264-75. [PMID: 33193890 DOI: 10.7150/jca.44727] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
7 Zięba S, Chechlińska M, Kowalik A, Kowalewska M. Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies. Gynecol Oncol 2020;158:498-506. [PMID: 32522421 DOI: 10.1016/j.ygyno.2020.05.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
8 Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Vergoni F, Amunni G, Fambrini M, Petraglia F, Noci I, Pillozzi S. Identification of a Gene Panel for Endometrioid Endometrial Cancer: a Possible Prognostic Value? Reprod Sci 2020;27:592-8. [DOI: 10.1007/s43032-019-00059-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Remmerie M, Janssens V. PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer. Front Oncol 2019;9:462. [PMID: 31214504 DOI: 10.3389/fonc.2019.00462] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
10 Mitamura T, Dong P, Ihira K, Kudo M, Watari H. Molecular-targeted therapies and precision medicine for endometrial cancer. Jpn J Clin Oncol 2019;49:108-20. [PMID: 30423148 DOI: 10.1093/jjco/hyy159] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
11 Sahasrabudhe NM, van der Horst JC, Spaans V, Kenter G, de Kroon C, Bosse T, van Vliet SJ, Jordanova ES. MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma. Front Oncol 2019;9:29. [PMID: 30761272 DOI: 10.3389/fonc.2019.00029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
12 Raman D, Pervaiz S. Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression. Redox Biol 2019;27:101105. [PMID: 30686777 DOI: 10.1016/j.redox.2019.101105] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
13 Basturea GN. Somatic Mutations. MATER METHODS 2018;8. [DOI: 10.13070/mm.en.8.2673] [Reference Citation Analysis]
14 Abdulrahman Z, Kortekaas KE, De Vos Van Steenwijk PJ, Van Der Burg SH, Van Poelgeest MI. The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy. Expert Opinion on Biological Therapy 2018;18:1223-33. [DOI: 10.1080/14712598.2018.1542426] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
15 Spaans VM, Scheunhage DA, Barzaghi B, de Kroon CD, Fleuren GJ, Bosse T, Jordanova ES. Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival. Gynecologic Oncology 2018;151:196-201. [DOI: 10.1016/j.ygyno.2018.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
16 Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 2019;16:105-22. [DOI: 10.1038/s41571-018-0115-y] [Cited by in Crossref: 146] [Cited by in F6Publishing: 153] [Article Influence: 29.2] [Reference Citation Analysis]
17 Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med 2018;7:5217-36. [PMID: 30589505 DOI: 10.1002/cam4.1501] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 19.2] [Reference Citation Analysis]
18 Pereira TS, Sant'anna JR, Morais JF, Yajima JPRS, Mathias PCF, Franco CCDS, Castro-Prado MAA. Assessment of bendamustine-induced genotoxicity in eukaryotic cells. Drug Chem Toxicol 2019;42:394-402. [PMID: 29681187 DOI: 10.1080/01480545.2018.1458236] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Trietsch MD, Oonk MH, Hawinkels LJ, Bor R, van Eendenburg JD, Ivanova Z, Peters AA, Nijman HW, Gaarenstroom KN, Bosse T. Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas. Oncotarget 2016;7:26192-205. [PMID: 27028855 DOI: 10.18632/oncotarget.8353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Spaans VM, Nyoman Bayu Mahendra I, Purwoto G, Trietsch MD, Osse M, Ter Haar N, Peters AAW, Fleuren GJ, Jordanova ES. The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway. Gynecol Oncol 2018;148:189-96. [PMID: 29113722 DOI: 10.1016/j.ygyno.2017.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
21 van Winkel E, de Leng W, Witteveen P, Jonges T, Willems S, Langenberg M. Next-Generation Sequencing in Gynaecological Tumours: The Prognostic and Predictive Value of the Most Common Mutations Found in Ovarian, Endometrial, and Cervical Tumours: Literature Review and the University Medical Centre Utrecht Next-Generation Sequencing Data. Pathobiology 2018;84:339-50. [DOI: 10.1159/000479797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Litwin TR, Clarke MA, Dean M, Wentzensen N. Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses 2017;9:E206. [PMID: 28771191 DOI: 10.3390/v9080206] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
23 Zou Y, Liu FY, Wu J, Wan L, Fang SF, Zhang ZY, Luo Y, Chen MH, Huang MZ, He M, Huang OP. Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma. Oncol Lett 2017;14:2427-31. [PMID: 28781678 DOI: 10.3892/ol.2017.6435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 van der Putten LJM, van Hoof R, Tops BBJ, Snijders MPLM, van den Berg-van Erp SH, van der Wurff AAM, Bulten J, Pijnenborg JMA, Massuger LFAG. Molecular profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis 2017;38:329-35. [PMID: 28203752 DOI: 10.1093/carcin/bgx008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
25 Winterhoff B, Konecny GE. Targeting fibroblast growth factor pathways in endometrial cancer. Current Problems in Cancer 2017;41:37-47. [DOI: 10.1016/j.currproblcancer.2016.11.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
26 van Gent MD, Nicolae-Cristea AR, de Kroon CD, Osse EM, Kagie MJ, Trimbos JB, Hazelbag HM, Smit VT, Bosse T. Exploring Morphologic and Molecular Aspects of Endometrial Cancer Under Progesterone Treatment in the Context of Fertility Preservation. Int J Gynecol Cancer 2016;26:483-90. [PMID: 26825822 DOI: 10.1097/IGC.0000000000000629] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
27 Clancy A, Spaans J, Weberpals J. The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy. Annals of Oncology 2016;27:1696-705. [DOI: 10.1093/annonc/mdw242] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
28 Fleitas T, Ibarrola-villava M, Ribas G, Cervantes A. MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. Cancer Treatment Reviews 2016;49:57-64. [DOI: 10.1016/j.ctrv.2016.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
29 Lebovitz CB, Robertson AG, Goya R, Jones SJ, Morin RD, Marra MA, Gorski SM. Cross-cancer profiling of molecular alterations within the human autophagy interaction network. Autophagy 2015;11:1668-87. [PMID: 26208877 DOI: 10.1080/15548627.2015.1067362] [Cited by in Crossref: 91] [Cited by in F6Publishing: 85] [Article Influence: 13.0] [Reference Citation Analysis]
30 Verlaat W, Snijders PJ, van Moorsel MI, Bleeker M, Rozendaal L, Sie D, Ylstra B, Meijer CJ, Steenbergen RD, Heideman DA. Somatic mutation in PIK3CA is a late event in cervical carcinogenesis. J Pathol Clin Res 2015;1:207-11. [PMID: 27499905 DOI: 10.1002/cjp2.27] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
31 Bumrungthai S, Munjal K, Nandekar S, Cooper K, Ekalaksananan T, Pientong C, Evans MF. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications. J Transl Med 2015;13:244. [PMID: 26209091 DOI: 10.1186/s12967-015-0611-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
32 Spaans VM, Trietsch MD, Peters AA, Osse M, Ter Haar N, Fleuren GJ, Jordanova ES. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. PLoS One 2015;10:e0133670. [PMID: 26197069 DOI: 10.1371/journal.pone.0133670] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
33 de Sant'Anna JR, Franco CC, Mathias PC, de Castro-Prado MA. Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells. PLoS One 2015;10:e0120675. [PMID: 25803314 DOI: 10.1371/journal.pone.0120675] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
34 Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015;28:836-44. [PMID: 25720322 DOI: 10.1038/modpathol.2015.43] [Cited by in Crossref: 251] [Cited by in F6Publishing: 260] [Article Influence: 31.4] [Reference Citation Analysis]
35 Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med 2014;12:255. [PMID: 25220666 DOI: 10.1186/s12967-014-0255-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
36 Trietsch MD, Spaans VM, ter Haar NT, Osse EM, Peters AA, Gaarenstroom KN, Fleuren GJ. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol Oncol 2014;135:149-55. [PMID: 25072932 DOI: 10.1016/j.ygyno.2014.07.094] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]